-
外観
白色～黄色～黄赤色粉末～結晶
-
効能
抗アレルギー薬, 抗炎症薬, H1受容体拮抗薬
-
説明
Alcaftadine, a histamine H1/H2 receptor antagonist, was approved in
the United States in 2010 for the prevention of itching and redness associated
with allergic conjunctivitis. Seasonal and perennial allergic conjunctivitis
affects up to 40% of the population worldwide. There are
numerous treatment options, with topical antihistamines being an effective
therapy. Some of the primary symptoms and signs of allergic conjunctivitis
are ocular itching and conjunctival redness. The pharmaceutical
market for conjunctivitis is substantial and steadily increasing.
-
使用
Alcaftadine is a H1 histamine receptor antagonist. Alcaftadine is used to prevent eye irritation and treat the signs and symptoms of allergic conjunctivitis.
-
定義
ChEBI: An imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergi
conjunctivitis.
-
臨床応用
Alcaftadine, an ophthalmic histamine H1 receptor antagonist,
was approved by the FDA for the prevention of itching associated
with allergic conjunctivitis and was launched under the trade
name Lastacaft in early 2011. Alcaftadine was discovered by
Janssen Pharmaceuticals and marketed by Vistakon Pharmaceuticals,
both subsidiaries of Johnson & Johnson. However, unlike other marketed drugs, the synthesis of alcaftadine was only mentioned
in the patents filed by Janssen’s scientists approximately twenty
years ago.
